3 Most common cause of cancer death in children is brain cancer 2 childhood brain cancers under investigation with paxalisib No FDA-approved therapies for DIPG or AT/RT 200k approximate patients per annum treated with whole brain radiotherapy in United States Multiple potential indications for EVT801, including lung cancer, bowel cancer, and kidney cancer 2H CY 2023 final data anticipated from pivotal study of paxalisib in 2H CY2023 Phase I study of EVT801 underway in France 8 ongoing clinical trials with paxalisib 6 countries involved in clinical development of paxalisib $4.2m of new equity capital raised through financing in FY2022 4 licensing partnerships in place 150+ years of aggregate drug development experience among management team 84-94% GBM forecast adoption of paxalisib in US, if approved by FDA Kazia Theraputics Limited Annual Report 2022 Triangle Insights research project, commission by Kazia Therapeutics AU$ CBTRUS Brown et al. (2018). J Clin Oncol. 36(5):483-491 United States, Canada, Spain, France, Switzerland, United Kingdom as at 30 June 2022 2022 at a Glance Chairman’s Letter CEO’s Report Key Milestones Pipeline Review ESG Financial Reports Our Collaborators
RkJQdWJsaXNoZXIy MjE2NDg3